Aethlon Medical Announces Second HIV/AIDS Treatment Site - Aethlon Medical, Inc.(OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon previously disclosed plans to initiate the 'first-in-man' clinical study of...
Aethlon Medical Announces Second HIV/AIDS Treatment Site Aethlon Medical Inc (AEMD) Stock Quote, Chart, News, Add to Watchlist Aethlon Medical, Inc.AEMD announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon previously...
Aethlon Medical Announces Second HIV/AIDS Treatment Site Company Website: http://www.aethlonmedical.com SAN DIEGO -- (Business Wire) Aethlon Medical, Inc.(OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon...
New type of ultraviolet diode could lead to compact anthrax detector A new class of ultraviolet photodiode could make possible a compact, reliable and cost-effective sensor to detect anthrax and other bioterrorism agents in the air.Research conducted at the Georgia Institute of Technology,...
Anthrax attacks in the U.S. 'suspect' awarded $2.8 million A former U.S.Army scientist has won his case against the United States Justice Department for being unfairly implicated in anthrax attacks in 2001.
Steven Hatfill accused the Justice Department of violating his privacy rights by...
DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clini -- DOR BioPharma, Inc.(DORB) ('DOR' or the 'Company'), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against...
Aethlon to start 1st human study of Hemopurifier for HIV/AIDS +0.00 +0.7% Released : Thursday, June 26, 2008 7:02 PM Aethlon to start 1st human study of Hemopurifier for HIV/AIDS Medical Device Daily Staff Writer Since 2001 Aethlon Medical (San Diego) has bannered its Hemopurifier as potentially the...
Aethlon Medical Featured in Medical Device Daily - Aethlon Medical, Inc.(OTCBB:AEMD) disclosed today that it has been featured in a cover story published in Medical Device Daily.
The story is accessible online at: www.aethlonmedical.com/pdfs/mdd062508.pdf About Aethlon Medical Aethlon...
Aethlon Medical Featured in Medical Device Daily , 7:30 AM EST News source: Business Wire Aethlon Medical, Inc.(OTCBB:AEMD) disclosed today that it has been featured in a cover story published in Medical Device Daily.
The story is accessible online at: www.aethlonmedical.com/pdfs...
BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland BioNeutral announced today that Steve Browand will direct the company's efforts to sell its advanced chemical technology products to the military, Homeland Security and governmental departments.Steve Browand said, 'I have reviewed the...
Aethlon CEO Discusses 'First-In-Man' HIV Study on CEOcast Aethlon Medical, Inc.(OTCBB:AEMD) disclosed this evening that its CEO, James A.
Joyce, is currently featured in an on-line interview with CEOcast, Inc.
During the interview, Mr.
Joyce discusses the 'first-in-man' clinical study of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardio VANCOUVER, June 26 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that it has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of...
Vical Advances RapidResponse DNA Vaccine Platform Under $6 Million Grant from NIH /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company has successfully completed first-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine...
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company has successfully completed first-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development...
Universal Detection Technology to Submit an Operational Requirements Document on Recommendation of the Departm Universal Detection Technology (www.udetection.com) (OTCBB: UDTT) (FRANKFURT: PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-...
Universal Detection Technology to Submit an Operational Requirements Document on Recommendation of the Departm , 4:01 AM EST Universal Detection Technology (www.udetection.com) (OTCBB: UDTT) (FRANKFURT: PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider...
Aethlon Medical Announces ''First-In-Man'' HIV/AIDS Treatment Study SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc.(OTCBB: AEMD.OB) announced today that it has entered into an agreement to initiate the first-in-man clinical study of a medical device to treat the Human Immunodeficiency Virus (HIV) which...
Aethlon Medical Announces ''First-In-Man'' HIV/AIDS Treatment Study Author : CA-AETHLON-MEDICAL Category : Press Release News Alerts by Email ( click here ) Press Release News | Home SAN DIEGO - (Business Wire) Aethlon Medical, Inc.(OTCBB:AEMD) announced today that it has entered into an agreement to...
Effective health messages may yield vaccine compliance among ER workers EUREKALERT Contact: Renee Cree 215-707-1583 In the event of a pandemic, healthy first responders will be essential to provide care for the infected Emergency room workers will be the first line of defense in the event of a disease pandemic...
Bioterrorism: Anthrax and Biotech Companies This is the second of two articles on bioterrorism and the companies involved in the field.The first article was on Smallpox.
This one is on Anthrax.
Anthrax is caused by the gram-positive bacterium Bacillus...
